中文名称: | 溴芬酸钠 | ||||
---|---|---|---|---|---|
英文名称: | Bromfenac sodium hydrate | ||||
别名: | 溴芬酸钠;[2-氨基-3-(4-溴苯甲酰基)苯基]乙酸钠;(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠;溴芬那酸钠;人内皮素3;溴芬那酸钠水合物;溴芬酸钠杂质;溴芬酸钠水合物;(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠水合物;溴酚酸钠 Bromfenac monosodium salt sesquihydrate | ||||
CAS No: | 120638-55-3 | 分子式: | C30H28Br2N2Na2O9 | 分子量: | 383.17 |
CAS No: | 120638-55-3 | ||||
分子式: | C30H28Br2N2Na2O9 | ||||
分子量: | 383.17 |
基本信息
产品编号: |
B11247 |
||||
产品名称: |
Bromfenac sodium hydrate |
||||
CAS: |
120638-55-3 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
||||
分子式: |
溶于液体 |
-80℃ |
两年 |
||
分子量 |
383.17 |
-20℃ |
一个月 |
||
化学名: |
sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate |
||||
Solubility (25°C): |
|||||
体外:
|
DMSO |
100mg/mL(130.49mM) |
|||
Ethanol |
Insoluble |
||||
Water |
100mg/mL(130.49mM) |
||||
体内(现配现用): |
1.请依序添加每种溶剂:PBS Solubility:33.33mg/mL(86.98mM);Clear solution; Need ultrasonic 2.请依序添加每种溶剂:10% DMSO→40% PEG300→5% Tween-80→45% saline,Solubility:≥2.5mg/mL(6.52mM);Clear solution |
||||
此⽅案可获得≥2.5mg/mL(6.52mM,饱和度未知)的澄清溶液。以1mL⼯作液为例,取100μL25.0mg/mL的澄清DMSO储备液加到400μLPEG300中,混合均匀;向上述体系中加⼊50μLTween-80,混合均匀;然后继续加⼊450μL⽣理盐⽔定容⾄1mL。 |
|||||
3.请依序添加每种溶剂:10% DMSO→90% (20% SBE-β-CD in saline) Solubility:≥2.5mg/mL(6.52mM);Clear solution |
|||||
此⽅案可获得≥2.5mg/mL(6.52mM,饱和度未知)的澄清溶液。以1mL⼯作液为例,取100μL25.0mg/mL的澄清DMSO储备液加到900μL20%的SBE-β-CD⽣理盐⽔⽔溶液中,混合均匀。 |
|||||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
1.3049mL |
6.5245mL |
13.0490mL |
5mM |
0.2610mL |
1.3049mL |
2.6098mL |
10mM |
0.1305mL |
0.6525mL |
1.3049mL |
50mM |
0.0261mL |
0.1305mL |
0.2610mL |
生物活性
产品描述 |
一种有效的和具有口服活性的 COX 抑制剂。 |
|
靶点 |
COX |
|
体外研究 |
Bromfenac (90μg/mL; 48 h) inhibits TGF-b1-induced extracellular matrix (ECM) synthesis and myofibroblast activation in HConFs and HPFs Bromfenac (30-90μg/mL; 48 h) decreases the protein and mRNA expression levels of FN, COL3, a-SMA, and survivin in a dosedependent manner in HConFs and HPFs Bromfenac (30-90μg/mL; 48 h) declines the phosphorylated protein levels of AKT, ERK1/2, and GSK-3b-S9 with dosage in HPFs and HConFs |
|
体内研究 |
Bromfenac (0.0032-3.16%; 100 or 200μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18h pretreatment time) in rats Bromfenac (0.032-3.16%; 100μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats Bromfenac (0.032-1.0%; 50μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs Bromfenac (0.0032-0.1%; 50μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats Bromfenac (0.32%; 50μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice |
|
Animal Model: |
Male Sprague-Dawley rats (150-250 g) are injected carrageenan |
|
Dosage: |
0.0032, 0.01, 0.032, 0.1, 0.32, 1.0, 3.16% (100 or 200μL) |
|
Administration: |
Rubbed onto the backs before 1-72 h of injected carrageenan |
|
Result: |
Produced significant anti-inflammatory activity when applied 1, 2, and 4 h prior to carrageenan challenge at 0.32%. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )